NASDAQ:KPRX - Nasdaq - US49721T5074 - Common Stock - Currency: USD
Taking everything into account, KPRX scores 3 out of 10 in our fundamental rating. KPRX was compared to 195 industry peers in the Pharmaceuticals industry. While KPRX seems to be doing ok healthwise, there are quite some concerns on its profitability. KPRX is valied quite expensively at the moment, while it does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -35.42% | ||
ROE | -50.85% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | -5.55 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 5.14 | ||
Quick Ratio | 5.14 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
3.08
-0.01 (-0.32%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 468.16 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0.4 | ||
P/tB | 0.55 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -35.42% | ||
ROE | -50.85% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 5.14 | ||
Quick Ratio | 5.14 | ||
Altman-Z | -5.55 |